RxDoctor Payments Data

Chadi Kaba, MD

Internal Medicine · Attleboro, MANPI 1811945694

Payments from drug & device makers

$1,455in general payments, 2019–2025

Across 103 payments — averaging $14.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$382
  • Novo Nordisk$231
  • GSK$214
  • Johnson & Johnson$119
  • AstraZeneca$90
  • Lilly USA, LLC$79
  • plus $340 from 9 others

What the payments were for

  • Food & beverage$1,455100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,455 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$132,771
Medicare patients
310
Services billed
1,734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$104,900
JardianceEmpagliflozin119$101,697
OzempicSemaglutide101$96,288
JanuviaSitagliptin Phosphate98$73,462
XareltoRivaroxaban43$54,993
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$50,930
Breo ElliptaFluticasone/Vilanterol48$18,047
TrulicityDulaglutide17$14,581
Tresiba Flextouch U-200Insulin Degludec11$10,860
Atorvastatin Calcium633$6,902
Arnuity ElliptaFluticasone Furoate17$6,389
Albuterol Sulfate HfaAlbuterol Sulfate178$5,399
Rosuvastatin Calcium155$5,363
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$5,288
Omeprazole328$4,494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Dilantin$382$107,355143 claims
Novo NordiskOzempic$231$96,288101 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$214$75,366132 claims
MerckJanuvia$35$73,46298 claims
Johnson & JohnsonXarelto$119$54,99343 claims
Lilly USA, LLCTrulicity$79$14,58117 claims
AbbVieSynthroid$37$1,61215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Attleboro

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →